Form 4 for KRYS Krystal Biotech, Inc.
Accepted 2023-02-28 00:00:00 ET · period of report 2023-02-26 · accession 0001298709-23-000013 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-02-28 | 2023-02-26 | KRYS | Krishnan Krish S | Pres, CEO, Dir, 10% | F - Tax | $78.46 | -4,350 | 1.73M | -0.3% | -$341.3K |
| DM | 2023-02-28 | 2023-02-28 | KRYS | Krishnan Krish S | Pres, CEO, Dir, 10% | A - Grant | $54.61 | +75.0K | 25.0K | New | +$4.10M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-26 | F | D | 4,350 | $78.46 | 1,734,338 | D | — | — | (F1) Represents tax withholding upon the vesting of 10,200 shares of restricted stock on February 26, 2023. (F2) The closing price on February 24, 2023 of the Company's common stock on NASDAQ. |
| 2 | Derivative | Stock Option (Right to Buy) | 2023-02-28 | A | A | 50,000 | $81.91 | 50,000 | D | $81.91 · — to 2033-02-28 | 50,000 Common Stock | (F5) The option vests in four equal annual installments beginning on February 28, 2024. |
| 3 | Derivative | Performance Stock Units | 2023-02-28 | A | A | 25,000 | $0.00 | 25,000 | D | — · — to — | 25,000 Common Stock | (F7) The number of PSUs in this column represents the number of shares of common stock the reporting person will receive assuming achievement of all of the corporate performance criteria set by the Company's Compensation Committee for this award. (F6) Each performance stock unit ("PSU") represents a contingent right to receive one share of the Company's common stock, subject to the achievement of certain corporate performance criteria during the year ended December 31, 2023, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. (F8) If any applicable portion of the performance criteria have been achieved, the award shall vest in two equal annual installments (February 28, 2024 and February 28, 2025). (F9) If the performance criteria are not achieved, the portion of the award which was capable of vesting on that date will expire. |